Engineering monoclonal antibodies for COVID-19 prophylaxis

The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.(1) engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Izadpanah, Amin, Rappaport, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915435/
https://www.ncbi.nlm.nih.gov/pubmed/35291730
http://dx.doi.org/10.1016/j.medj.2022.02.004
_version_ 1784668021989572608
author Izadpanah, Amin
Rappaport, Jay
author_facet Izadpanah, Amin
Rappaport, Jay
author_sort Izadpanah, Amin
collection PubMed
description The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.(1) engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide prophylactic protection against infection in rhesus macaques.
format Online
Article
Text
id pubmed-8915435
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-89154352022-03-11 Engineering monoclonal antibodies for COVID-19 prophylaxis Izadpanah, Amin Rappaport, Jay Med (N Y) Viewpoint The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.(1) engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide prophylactic protection against infection in rhesus macaques. Published by Elsevier Inc. 2022-03-11 2022-03-11 /pmc/articles/PMC8915435/ /pubmed/35291730 http://dx.doi.org/10.1016/j.medj.2022.02.004 Text en © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Viewpoint
Izadpanah, Amin
Rappaport, Jay
Engineering monoclonal antibodies for COVID-19 prophylaxis
title Engineering monoclonal antibodies for COVID-19 prophylaxis
title_full Engineering monoclonal antibodies for COVID-19 prophylaxis
title_fullStr Engineering monoclonal antibodies for COVID-19 prophylaxis
title_full_unstemmed Engineering monoclonal antibodies for COVID-19 prophylaxis
title_short Engineering monoclonal antibodies for COVID-19 prophylaxis
title_sort engineering monoclonal antibodies for covid-19 prophylaxis
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915435/
https://www.ncbi.nlm.nih.gov/pubmed/35291730
http://dx.doi.org/10.1016/j.medj.2022.02.004
work_keys_str_mv AT izadpanahamin engineeringmonoclonalantibodiesforcovid19prophylaxis
AT rappaportjay engineeringmonoclonalantibodiesforcovid19prophylaxis

Ejemplares similares